Recent Patents on CNS Drug Discovery

Vincenzo Di Marzo
Istituto di Chimica Biomolecolare (I.C.B.)
Consiglio Nazionale delle Ricerche (C.N.R.)
Via Campi Flegrei 34
Pozzuoli, Napoli 80078


Glycine Transporter Inhibitors as Therapeutic Agents for Schizophrenia

Author(s): Kenji Hashimoto

Affiliation: Division of ClinicalNeuroscience, Chiba University Center for Forensic Mental Health, 1-8-1Inohana, Chiba 260-8670, Japan;

Keywords: NMDA receptor, glycine, glycine transporter, glia, cognition, schizophrenia


Multiple lines of evidence suggest that a dysfunction in the glutamatergic neurotransmission via the N-methyl- D-aspartate (NMDA) receptors contributes to the pathophysiology of psychiatric diseases including schizophrenia. The potentiation of NMDA receptor function may be a useful approach for the treatment of diseases associated with NMDA receptor hypofunction. One possible strategy is to increase synaptic levels of glycine by blocking the glycine transporter-1 (GlyT-1) in glia cells, since glycine acts as a co-agonist site on the NMDA receptor. In this article, the author reviews the recent important patents on GlyT-1 inhibitors for treatment of schizophrenia and other psychiatric diseases associated with the NMDA receptor hypofunction.

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

Page: [43 - 53]
Pages: 11
DOI: 10.2174/157488906775245336